Integrative Statistics, Machine Learning and Artificial Intelligence Neural Network Analysis Correlated CSF1R with the Prognosis of Diffuse Large B-Cell Lymphoma
暂无分享,去创建一个
Naoya Nakamura | Joaquim Carreras | Yara Yukie Kikuti | Masashi Miyaoka | Haruka Ikoma | Yusuke Kondo | Atsushi Ito | Shinichiro Hiraiwa | Giovanna Roncador | Rifat Hamoudi | Juan F. García | Sakura Tomita | Yoshihiro Komohara | R. Hamoudi | N. Nakamura | Y. Komohara | Shinichiro Hiraiwa | S. Tomita | G. Roncador | Y. Kikuti | J. Carreras | Yusuke Kondo | Haruka Ikoma | Atsushi Ito | M. Miyaoka
[1] Jianguo Xu,et al. CD47: the next checkpoint target for cancer immunotherapy. , 2020, Critical reviews in oncology/hematology.
[2] Emili Montserrat,et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.
[3] Juan F. García,et al. CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma , 2015, PloS one.
[4] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Wilcox. A three‐signal model of T‐cell lymphoma pathogenesis , 2016, American journal of hematology.
[6] J. Pollard,et al. Diverse Functions of Macrophages in Different Tumor Microenvironments. , 2018, Cancer research.
[7] Joaquim Carreras,et al. Artificial Intelligence Analysis of the Gene Expression of Follicular Lymphoma Predicted the Overall Survival and Correlated with the Immune Microenvironment Response Signatures , 2020, Mach. Learn. Knowl. Extr..
[8] The UniProt Consortium,et al. UniProt: a worldwide hub of protein knowledge , 2018, Nucleic Acids Res..
[9] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[10] K. Gu,et al. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count , 2019, BMC Cancer.
[11] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[12] N. Nakamura,et al. MYD88 (L265P) Mutation in Malignant Lymphoma Using Formalin-Fixed Paraffin-Embedded Section. , 2013, Journal of clinical and experimental hematopathology : JCEH.
[13] W. Chan,et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] L. Staudt,et al. Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.
[15] Ash A. Alizadeh,et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. , 2010, Blood.
[16] K. Elenitoba-Johnson,et al. Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability , 2019, Clinical Cancer Research.
[17] K. Ando,et al. Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients , 2018, The American journal of surgical pathology.
[18] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[19] Juan F. García,et al. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS) , 2017, Histopathology.
[20] Jun Zhu,et al. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma , 2011, Journal of hematology & oncology.
[21] R. Hamoudi,et al. A Combination of Multilayer Perceptron, Radial Basis Function Artificial Neural Networks and Machine Learning Image Segmentation for the Dimension Reduction and the Prognosis Assessment of Diffuse Large B-Cell Lymphoma , 2021, AI.
[22] R. Gascoyne,et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.
[23] R. Hamoudi,et al. Artificial Intelligence Analysis of Gene Expression Data Predicted the Prognosis of Patients with Diffuse Large B-Cell Lymphoma. , 2020, The Tokai journal of experimental and clinical medicine.
[24] Y. Okuno,et al. Expression of IL‐34 correlates with macrophage infiltration and prognosis of diffuse large B‐cell lymphoma , 2019, Clinical & translational immunology.
[25] A. Lánczky,et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets , 2018, Scientific Reports.
[26] S. McWeeney,et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples , 2018, Oncotarget.
[27] A. Rosenwald,et al. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation , 2019, Journal of clinical and experimental hematopathology : JCEH.
[28] W. Denny,et al. Small-molecule CSF1R kinase inhibitors; review of patents 2015-present , 2020, Expert opinion on therapeutic patents.
[29] C. Ries,et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. , 2017, Journal for immunotherapy of cancer.
[30] R. Hamoudi,et al. A Single Gene Expression Set Derived from Artificial Intelligence Predicted the Prognosis of Several Lymphoma Subtypes; and High Immunohistochemical Expression of TNFAIP8 Associated with Poor Prognosis in Diffuse Large B-Cell Lymphoma , 2020, Applied Informatics.
[31] Wen-Qi Jiang,et al. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study , 2017, Chinese journal of cancer.
[32] C. Lindskog,et al. A pathology atlas of the human cancer transcriptome , 2017, Science.
[33] James J. Driscoll,et al. Overall Survival: Still the Gold Standard: Why Overall Survival Remains the Definitive End Point in Cancer Clinical Trials , 2009, Cancer journal.
[34] Xiaoyun Lu,et al. Small-Molecule CSF1R Inhibitors as Anticancer Agents. , 2019, Current medicinal chemistry.
[35] R. Bociek,et al. CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial , 2012 .
[36] K. Akashi,et al. Combination of CD47 and signal‐regulatory protein‐α constituting the “don’t eat me signal” is a prognostic factor in diffuse large B‐cell lymphoma , 2020, Cancer science.
[37] R. Xiang,et al. M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma , 2016, Scientific Reports.
[38] A. López-Guillermo,et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] K. Ohshima,et al. Role of tumor‐associated macrophages in hematological malignancies , 2015, Pathology international.
[40] J. Andrechak,et al. Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function , 2020, Antibody therapeutics.
[41] L. Staudt,et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy , 2011, Haematologica.
[42] P. Boonstra,et al. Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia , 2016, Clinical Cancer Research.
[43] R. Fehrmann,et al. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL , 2019, Cancer Immunology Research.